Literature DB >> 23325740

Validation of a free phenytoin assay on Cobas c501 analyzer using calibrators from Cobas Integra free phenytoin assay by comparing its performance with fluorescence polarization immunoassay for free phenytoin on the TDx analyzer.

Amitava Dasgupta1, Bonnette Davis, Loretta Chow.   

Abstract

For many years, fluorescence polarization immunoassay (FPIA) on the TDx analyzer has been used for determination of free phenytoin concentration. Recently Abbott Laboratories decided to discontinue the TDx analyzer and related assays on this analyzer. Free phenytoin assay is also available from Roche Diagnostics for application on the Cobas Integra analyzer (fluorescence polarization assay) but not on Cobas c510 analyzer. Free phenytoin calibrators from the Cobas Integra free phenytoin assay and the reagents from the KIMSphenytoin assay were used for the determination of free phenytoin on the Cobas c501 analyzer. The intra-run and inter-run precisions were both <7.2%. The assay was linear from 0.2 to 4 μg/ml. The free phenytoin assay on the Cobas c501 was compared with the FPIAassay on the TDx analyzer using sera from 25 patients receiving phenytoin (phenytoin concentration between 0.3 and 3.7 μg/ml). The following regression equation was observed: y = 0.9899 x + 0.0408 (r = 0.98, n = 25). In conclusion, the free phenytoin assay on the Cobas c501 analyzer is a valid alternative to free phenytoin assay on the TDx analyzer.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23325740      PMCID: PMC6807318          DOI: 10.1002/jcla.21536

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  13 in total

1.  Plasma total phenytoin: a possibly misleading test in developing countries.

Authors:  C Fedler; M J Stewart
Journal:  Ther Drug Monit       Date:  1999-04       Impact factor: 3.681

2.  Determination of free levels of phenytoin in human plasma by liquid chromatography/tandem mass spectrometry.

Authors:  S Bardin; J C Ottinger; A P Breau; T J O'Shea
Journal:  J Pharm Biomed Anal       Date:  2000-08-15       Impact factor: 3.935

3.  Clinical evaluation of plasma free phenytoin measurement and factors influencing its protein binding.

Authors:  Takuya Iwamoto; Yoshiyuki Kagawa; Yutaka Naito; Shigeki Kuzuhara; Masahiro Okuda
Journal:  Biopharm Drug Dispos       Date:  2006-03       Impact factor: 1.627

4.  Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors.

Authors:  I Sjöholm; A Kober; I Odar-Cederlöf; O Borgåa
Journal:  Biochem Pharmacol       Date:  1976-05-15       Impact factor: 5.858

5.  Serum concentrations of free diphenylhydantoin and their relationship to clinical intoxication.

Authors:  H E Booker; B Darcey
Journal:  Epilepsia       Date:  1973-06       Impact factor: 5.864

6.  Alteration of drug-protein binding in renal disease.

Authors:  M M Reidenberg; D E Drayer
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

7.  Endogenous accumulation products and serum protein binding in uremia.

Authors:  P J McNamara; D Lalka; M Gibaldi
Journal:  J Lab Clin Med       Date:  1981-11

8.  Evidence-based implementation of free phenytoin therapeutic drug monitoring.

Authors:  M Burt; D C Anderson; J Kloss; F S Apple
Journal:  Clin Chem       Date:  2000-08       Impact factor: 8.327

9.  Phenytoin toxicity associated with hypoalbuminemia in critically ill patients.

Authors:  J Lindow; E F Wijdicks
Journal:  Chest       Date:  1994-02       Impact factor: 9.410

10.  Differences between the measured and calculated free serum phenytoin concentrations in epileptic patients.

Authors:  Ji-Man Hong; Young-Chul Choi; Won-Joo Kim
Journal:  Yonsei Med J       Date:  2009-08-19       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.